Covaxin. "These results compare well with the 65.2% efficacy against the delta variant obtained during the controlled phase III clinical trials of Covaxin conducted among the general population.
This study also shows that Covaxin meets the WHO efficacy criteria for Covid-19 vaccines for the dreaded Delta variant," the company said.
The development of the country's indigenous COVID-19 vaccine Covaxin is a true success story for public-private partnerships in India, which is based on mutual respect, trust and transparency, said Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech.
Bharat Biotech commends the investigators from #AIIMS on the BBV152 study published in Lancet Infectious Diseases. These results provide evidence for